Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Astellas, Shionogi Enthusiastic about Joint Research with Academia
March 30, 2009
- Studies Voluntarily Conducted by Physicians Must Be Funded by Contracts
March 30, 2009
- Takara Bio Supplies RetroNectin for 46th Clinical Trial
March 30, 2009
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 30, 2009
- JAPhMed to Be Incorporated into Medical Society in April
March 30, 2009
- Takara Bio Licenses LA-PCR Methods to Biotools of Spain
March 30, 2009
- LDP Diet Members Not Persuaded about Safety of Online Sale
March 30, 2009
- 570 New DPC Hospitals Expected in FY2009
March 23, 2009
- Pfizer Stops PIII Study for Sutent Early
March 23, 2009
- TPNA Launches Febuxostat in US Market
March 23, 2009
- Solasia Initiates PI Study of SP-01 in Japan
March 23, 2009
- Janssen Surpasses ¥100 Bil. Mark in 2008
March 23, 2009
- Toray, Taiho to Jointly Develop Drug for OAB
March 23, 2009
- Ono Allies with Xention
March 23, 2009
- Zonisamide Might Have Neuroprotective Effects
March 23, 2009
- Gilead Sciences to Acquire CVT
March 23, 2009
- LDP Diet Members Inaugurate Federation on Online Sale of Drugs
March 23, 2009
- Novartis Launches 4 New Drugs at Same Time
March 23, 2009
- More Time Needed to Ensure Safety of Drugs Sold Online: Council
March 23, 2009
- DSP to Promote Trerief as 3rd-Line Anti-Parkinson Drug
March 23, 2009
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…